Key result
AC-73 mitigated CVB3-induced myocarditis in mice by inhibiting T cell activation and the recruitment of immune cells to the heart.
Why the study?
Viral myocarditis is characterized by cardiac inflammation, and the CD147 inhibitor AC-73 was evaluated to explore whether it could alleviate cardiac inflammation induced by CVB3.
Does AC-73 alleviate cardiac inflammation in mice with CVB3-induced acute viral myocarditis?
Does AC-73 alleviate cardiac inflammation in mice with CVB3-induced acute viral myocarditis?
Inhibition of CD147 with AC-73 mitigates CVB3-induced viral myocarditis in mice by suppressing T cell activation and immune cell recruitment.
Supports CD147 inhibition in viral myocarditis models; hypothesis-generating and should not change practice.
Viral myocarditis (VMC) is a common disease characterized by cardiac inflammation. AC-73, an inhibitor of CD147, disrupts the dimerization of CD147, which participates in the regulation of inflammation. To explore whether AC-73 could alleviate cardiac inflammation induced by CVB3, mice were injected intraperitoneally with AC-73 on the fourth day post-infection (dpi) and sacrificed on the seventh dpi. Pathological changes in the myocardium, T cell activation or differentiation, and expression of cytokines were analyzed using H&E staining, flow cytometry, fluorescence staining and multiplex immunoassay. The results showed that AC-73 alleviated cardiac pathological injury and downregulated the percentage of CD45+CD3+ T cells in the CVB3-infected mice. The administration of AC-73 reduced the percentage of activated CD4+ and CD8+ T cells (CD69+ and/or CD38+) in the spleen, while the percentage of CD4+ T cell subsets in the spleen was not changed in the CVB3-infected mice. In addition, the infiltration of activated T cells (CD69+) and macrophages (F4/80+) in the myocardium also decreased after the AC-73 treatment. The results also showed that AC-73 inhibited the release of many cytokines and chemokines in the plasma of the CVB3-infected mice. In conclusion, AC-73 mitigated CVB3-induced myocarditis by inhibiting the activation of T cells and the recruitment of immune cells to the heart. Thus, CD147 may be a therapeutic target for virus-induced cardiac inflammation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied CVB3-Induced Acute Viral Myocarditis. AC-73 vs. Untreated CVB3-infected mice was evaluated on Cardiac pathological injury, T cell activation or differentiation, and expression of cytokines. AC-73 mitigated CVB3-induced myocarditis in mice by inhibiting T cell activation and the recruitment of immune cells to the heart.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: